A Prospective, Multicenter, Open Label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus (RAD001) With Basiliximab, Corticosteroids and Lower Levels Versus Higher Levels of Tacrolimus in De Novo Renal Transplant Recipients.

Trial Profile

A Prospective, Multicenter, Open Label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus (RAD001) With Basiliximab, Corticosteroids and Lower Levels Versus Higher Levels of Tacrolimus in De Novo Renal Transplant Recipients.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Nov 2011

At a glance

  • Drugs Everolimus (Primary) ; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Adverse reactions; Registrational
  • Sponsors Novartis
  • Most Recent Events

    • 14 May 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top